# Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC

> **NCT05062837** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 62 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Hepatectomy Combined With Camrelizumab and Apatinib

## Key facts

- **NCT ID:** NCT05062837
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-12-31
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05062837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05062837, "Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05062837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*